In Vitro Lung Models Market Forecast (2025-2031)

In Vitro Lung Models Market Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (3D Model and 2D Model), Application (Drug Discovery and Toxicology Studies, Physiological Research, Regenerative Medicine, and Others), End User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, and Others), and Geography

Publication Month : Jun 2025

  • Report Code : TIPRE00006695
  • Category : Life Sciences
  • Status : Published
  • No. of Pages : 150
Inquire Before Buy

PRICING

$4450

$3560

The In Vitro lung models market size is projected to reach US$ 1,530.11 million by 2031 from US$ 446.35 million in 2024. The market is estimated to register a CAGR of 19.4% during 2025–2031. Applications of 3D cultures and AI in oncology are likely to bring new trends to the market in the coming years.

In Vitro Lung Models Market Analysis

The market growth is driven by the surging prevalence of respiratory diseases and the rising adoption of in vitro models as an alternative to animal testing. Precision-cut lung slices (PCLS) allow the study of airway constriction and inflammation, facilitating the evaluation of novel therapeutic targets for asthma and other respiratory conditions. Lung-on-a-chip devices have been developed to replicate the physiological conditions of the human lung. The University of Michigan's "lung-on-a-chip" device uses human lung-tissue cells cultured on a plastic chip with microscopic channels to simulate the conditions inside the lungs, providing new insights into diseases. Thus, the increasing demand for effective treatments and research models fuels the growth of the in vitro lung model market.

In Vitro Lung Models Market Overview

Per the Centers for Disease Control and Prevention (CDC) data, asthma affected ~25 million people in the US in 2021. According to the WHO, in 2022, ~2.5 million individuals were diagnosed with lung cancer, and over 1.8 million people died from the disease. As per the WHO data, from the emergence of COVID-19 in late 2019 to April 2023, the number of reported cases was ~762 million, with 6.81 million associated deaths. This rising incidence of respiratory diseases is spurring the demand for advanced research models to understand disease mechanisms and develop effective treatments. In vitro lung models provide valuable platforms for studying disease mechanisms and testing potential therapies, supporting the development of effective treatments.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

In Vitro Lung Models Market: Strategic Insights

in-vitro-lung-model-market
Market Size Value inUS$ 185.80 Million in 2018
Market Size Value byUS$ 701.81 Million by 2027
Growth rateCAGR of 16.2% from 2019-2027
Forecast Period2019-2027
Base Year2019
Analyst Image

Mrinal

Have a question?

Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Analyst Image  Speak to Analyst

In Vitro Lung Models Market Drivers and Opportunities

Rising Adoption of In Vitro Models as an Alternative to Animal Testing

In vitro lung models offer an alternative to animal testing, enabling researchers to study human lung biology and diseases with greater precision and relevance. These in vitro models closely replicate the alveoli, airways, vasculature, mesothelium, and interstitium of native lung tissue. Their multicellular composition allows for an accurate simulation of spatial and functional dynamics found in situ lungs, making them an indispensable tool in biomedical research. As a result, researchers are now adopting lung models for a wide range of applications, from disease modeling to toxicology and drug development. The 2021 Innovation grant spurred the development of a synthetic lung model at the University of Reading. The winner, Dr. Hisham Al-Obaidi, and his team at the University of Reading were awarded a US$ 8,692.19 (£6,500) Innovation Grant in 2021 to develop a synthetic lung model aimed at replacing animal testing. The project focuses on creating an in vitro lung model to evaluate the effectiveness of antimicrobial agents, with the goal of providing an in vitro model that resembles the human lungs to traditional animal-based methods. The team opted for a non-biological model designed to simulate drug behavior in the human respiratory system. Their approach demonstrated that the tested drug could penetrate deep into the lung-like structure, pass through a hydrogel layer simulating mucus, and eliminate bacterial presence. Now, the team is in the process of validating the model. This process includes testing the impact of inhaled antibiotic particles on mature bacterial colonies cultured on agar plates to determine whether any viable bacteria remain after treatment. This model could serve as a valuable tool for predicting antimicrobial efficacy in humans while reducing reliance on animal testing.

Surging Funding and Investments for In Vitro Models

In vitro lung models offer more accurate simulations of human lung physiology than traditional 2D cultures. This advancement has attracted investments from the public and private sectors. Emulate, a biotechnology company specializing in Organs-on-Chips technology, has attracted investments to commercialize human cell-based models that replicate organ-level functions. In September 2021, Emulate raised US$ 82 million in a Series E funding round led by the Founders Fund, underscoring the confidence in organ-on-chip platforms for drug testing and disease modeling. In December 2024, Newcells Biotech, a UK-based biotech startup specializing in the development of advanced in vitro models for drug discovery, secured US$ 1.60 million (£1.2 million) in funding from Mercia Ventures, Northstar Ventures, and North East Finance. Founded in 2015 as a spin-out from Newcastle University, Newcells develops 3D tissue models that replicate the retina, kidney, and lung. These models are used to predict drug safety and efficacy. The funding will enable Newcells to expand its customer base, form new partnerships, and enhance its offerings in key international markets. Thus, such funding and investments facilitate the development of more effective treatments for respiratory diseases, offering promising future opportunities for companies in the healthcare and biotechnology sectors.

In Vitro Lung Models Market Report Segmentation Analysis

Key segments that contributed to the derivation of the In Vitro Lung Models Market analysis are technology, animal type, route of administration, end user, and geography.

  • Based on type, the In Vitro lung models market is bifurcated into 3D Models and 2D Models. The 3D model held the largest share of the In Vitro lung models market in 2024, and it is expected to register a significant CAGR during 2025–2031.
  • By application, the market is categorized into drug discovery and toxicology studies, physiological research, regenerative medicine, and others. The drug discovery and toxicology studies segment held the largest share of the In Vitro lung models market in 2024.
  • In terms of end user, the In Vitro lung models market is segmented into pharmaceutical and biotechnology companies, academic and research institutes, and others. The pharmaceutical and biotechnology companies segment held the largest share of the In Vitro lung models market in 2024, and it is expected to register a significant CAGR during 2025–2031.

In Vitro Lung Models Market Share Analysis by Geography

The geographic scope of the In Vitro Lung Models Market report is mainly divided into five major regions: North America, Europe, Asia Pacific, the Middle East and Africa, and South and Central America. North America dominated the market in 2024. The technological innovations and strong biomedical research infrastructure contribute to the growth of the market in North America. Technological innovations have played a pivotal role in enhancing the complexity and functionality of in vitro models. Advancements in tissue engineering, microfluidics, and organ-on-a-chip technologies have enabled the development of more accurate and predictive models for drug discovery and toxicology studies. These innovations facilitate the creation of models that closely mimic human lung physiology, improving the reliability of preclinical testing and reducing the need for animal experiments.

The region is home to leading academic institutions, research organizations, and pharmaceutical companies that are at the forefront of in vitro lung modeling research. These institutions have access to state-of-the-art facilities, cutting-edge technologies, and skilled researchers, enabling them to innovate and advance the field. The market growth is also fueled by the presence of major industry players, the expansion of animal welfare programs and regulations, and a well-established healthcare infrastructure. Also, favorable government initiatives and a rising number of research collaborations further boost the growth of the In Vitro lung models market

In Vitro Lung Models Market Report Scope

In Vitro Lung Models Market News and Recent Developments

The In Vitro lung models market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. Key developments in the market are listed below:

  • Emulate, Inc., a provider of next-generation in vitro models, welcomed the U.S. Food and Drug Administration’s (FDA) newly announced plan to reduce reliance on animal testing in preclinical safety studies. The FDA’s strategic roadmap outlines how New Approach Methodologies (NAMs), including organ chips, advanced computational modeling, and other in vitro assays, will help streamline drug development, lower costs, and improve patient safety. (Source: Emulate Inc., Company Website, April 2025)
  • Lonza, a global manufacturing partner to the pharmaceutical, biotech, and nutraceutical markets, today announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, California (US) from Roche for US$ 1.2 billion. (Source: Lonza, Company Website, March 2025).

In Vitro Lung Models Market Report Coverage and Deliverables

The "In Vitro Lung Models Market Size and Forecast (2021–2031)" report provides a detailed analysis of the market covering below areas:

  • In Vitro Lung Models Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
  • In Vitro Lung Models Market trends, as well as market dynamics such as drivers, restraints, and key opportunities
  • Detailed PEST and SWOT analysis
  • In Vitro Lung Models Market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
  • Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the In Vitro lung models Market
  • Detailed company profiles
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

Type ; Application and Geography

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

US, Canada, Mexico, UK, Germany, Spain, Italy, France, India, China, Japan, South Korea, Australia, UAE, Saudi Arabia, South Africa, Brazil, Argentina

Frequently Asked Questions


What are the factors driving the In Vitro lung models Market growth?

The surging prevalence of respiratory diseases and the rising adoption of in vitro models as an alternative to animal testing fuel the market growth.

Which region dominated the In Vitro lung models Market in 2024?

North America dominated the market in 2024.

What are the future trends in the In Vitro lung models Market?

The application of 3D cultures and AI in oncology is expected to emerge as a prime trend in the market in the coming years.

Which are the leading players operating in the In Vitro lung models Market?

MatTek Corp, Lonza Group AG, Emulate, Inc, CN Bio Innovations Ltd, PromoCell GmbH, Charles River Laboratories International Inc, MIMETAS BV, InSphero AG, Organovo Holdings Inc, Draper, Inc, Epithelix, AlveoliX AG, and American Type Culture Collection (ATCC) are among the key players in the market.

What is the expected CAGR of the In Vitro lung models Market?

The market is expected to register a CAGR of 19.4% during 2025–2031.

What would be the estimated value of the In Vitro lung models Market by 2031?

The market value is expected to reach US$ 1,530.11 million by 2031.

List of Companies - In Vitro Lung Models Market

  • MatTek Corp
  • Lonza Group AG
  • Emulate, Inc
  • CN Bio Innovations Ltd
  • PromoCell GmbH
  • Charles River Laboratories International Inc
  • MIMETAS BV
  •  InSphero AG
  • Organovo Holdings Inc
  • Draper, Inc
  • Epithelix, AlveoliX AG
  • American Type Culture Collection (ATCC)

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • 3.1 Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • 3.2 Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • 3.3 Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • 3.4 Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Trends and growth analysis reports related to In Vitro Lung Models Market